---
title: "ESMO 2025: CSTONE PHARMA-B reveals phase I clinical trial data for CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody)"
description: "According to the Zhitong Finance APP, CSTONE PHARMA-B announced that the company will present preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 tri-specific antibody) and the"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261789427.md"
published_at: "2025-10-20T01:03:08.000Z"
---

# ESMO 2025: CSTONE PHARMA-B reveals phase I clinical trial data for CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody)

> According to the Zhitong Finance APP, CSTONE PHARMA-B announced that the company will present preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 tri-specific antibody) and the design of the Phase Ib clinical study of CS5001 (ROR1 antibody-drug conjugate ADC) for the first time at the 2025 European Society for Medical Oncology (ESMO) annual meeting

Zhitong Finance APP news, CSTONE PHARMA-B (02616) announced that the company will present preliminary data from the Phase I clinical study of CS2009 (PD1/VEGF/CTLA-4 tri-specific antibody) and the design of the Phase Ib clinical study of CS5001 (ROR1 antibody-drug conjugate ADC) for the first time at the 2025 European Society for Medical Oncology (ESMO) annual meeting

### Related Stocks

- [02616.HK - CSTONE PHARMA-B](https://longbridge.com/en/quote/02616.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CStone secures FDA clearance to begin CS2009 Phase II trial | CStone Pharmaceuticals has received FDA clearance for its IND application, allowing the initiation of a Phase II trial f | [Link](https://longbridge.com/en/news/276114397.md) |
| CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II clinical trial of its t | [Link](https://longbridge.com/en/news/276018493.md) |
| 13:03 ETBelay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) | Belay Diagnostics has announced the validation of its Summit™ 2.0 Comprehensive Genomic Profile assay for cerebrospinal  | [Link](https://longbridge.com/en/news/276259162.md) |
| CStone Pharmaceuticals Secures NMPA Approval for Phase II Trials of CS2009 Tri-Specific Antibody | CStone Pharmaceuticals has received approval from the China National Medical Products Administration (NMPA) for Phase II | [Link](https://longbridge.com/en/news/264105327.md) |
| CStone Pharmaceuticals Unveils Phase I Data for CS2009 Trispecific Antibody at ESMO 2025 | CStone Pharmaceuticals has revealed preliminary Phase I clinical data for its trispecific antibody CS2009, targeting PD- | [Link](https://longbridge.com/en/news/261784961.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.